US / en / USD

Somavedic

Sleep and Mood in the Combined BrainTap + Somavedic Pilot

A six-week pilot with 20 adults evaluated BrainTap and Somavedic together. The team reported statistically significant improvements in overall sleep quality, mood and stress scores during the combined program.

Download study
Combined pilot: intervention protocol, questionnaire outcomes, and findings

Original document

Study methodology and parameters

Overview of methodology, monitored indicators, and research institution background.

Source

BrainTap × Somavedic, 2023

Download (4 pages)
Publication type
Pilot report (2023); peer review not identified
Research institution
Collaborative evaluation by BrainTap Technologies and Somavedic Technologies
Tested device
Somavedic; model not identified
Study type
Six-week combined pilot study
Investigated cohort
20 healthy adults
Comparison methodology
Participants’ own baseline during combined BrainTap and Somavedic use
Observation period
6 weeks of daily use
Monitored parameters
Sleep quality, emotional wellbeing, perceived stress, and mood

Participants and methods

Twenty healthy adults followed a combined program for six weeks: two BrainTap sessions daily and time near a Somavedic device, particularly during sleep. The Somavedic model is not identified in the report.

Participants completed the Depression Anxiety Stress Scales (DASS), Profile of Mood States (POMS) and Pittsburgh Sleep Quality Index (PSQI) before and after the program. The analysis compared the group’s starting and final questionnaire scores.

Results

  • Global PSQI sleep quality, POMS mood, and DASS stress and depression scores improved significantly. PSQI sleep latency, duration, disturbances and daytime dysfunction subscales also improved significantly.
  • Changes in subjective sleep quality, sleep efficiency and sleep-medication use were not statistically significant. The report labels the DASS anxiety change as not statistically significant.

Study context

Participants used both technologies together, so the findings describe the combined program. The study used participants’ own baseline, with no separate control or placebo group and no blinding. It reports questionnaire outcomes, not HRV measurements.

Source: BrainTap + Somavedic pilot report (2023). The authors include BrainTap Technologies and Somavedic Technologies affiliations. Journal peer review and a separate funding statement are not identified in the report.

Related paths

Continue into more evidence and explanation

Why Somavedic